The Venture Codex

Participated · Series C · Jan 2026

Ukko is developing next-generation allergy treatments by re-engineering allergenic proteins and delivering them via mRNA/LNP formulations to avoid severe reactions while retraining the immune system. Its lead drug candidate, UKK-0018, targets peanut allergy and has shown strong tolerability and protection against anaphylaxis in animal models. Regulatory clearance has been secured in Australia and New Zealand to launch a Phase 1/2a trial in 1H 2026 that will enroll roughly 32–40 adult subjects, with initial data expected in early 2027. The company’s proprietary platform is intended to be scalable to additional allergens such as milk, tree nuts, and respiratory triggers. Ukko recently strengthened its leadership team by appointing Matt Ottmer as COO and Grace Chen-Philips, M.D., as CMO. Headquartered in Boston, Massachusetts, and Rechovot, Israel, Ukko believes its approach can overcome safety and tolerability limitations of existing exposure-based desensitization methods. A $45 million Series C round is expected to fund operations, including the planned clinical study, through 2027.

Led · Seed · Jun 2023

Qlog develops a Healthcare Operations Platform built within the healthcare ecosystem to create real-time, crowd-sourced data flow and visibility. The company specializes in crowd-sourced ERP and RTLS resource-management tools for hospitals and clinics. Its platform gives healthcare institution managers and stakeholders full data visibility to optimize equipment utilization and minimize medication and equipment loss and waste. The technology is positioned to improve operational efficiency and patient safety. Qlog is led by Founder and CEO Dr. Amit Lehavi. The company intends to use recent funding to support expansion of its international commercial activities in the US, UK and EU.

Participated · Series A · Mar 2022

CVAid Medical has developed an AI-driven platform that enables neurological examinations from smartphone video and voice recordings, processing image and audio data in the cloud with in-house algorithms for real-time analysis and comparison with stored medical records. The system provides clinicians with immediate diagnostic output on whether a patient has had a stroke and an assessment of severity, plus tools to support rapid treatment decisions. The technology is also designed for use by non-professionals (e.g., retirement-home staff or family members) to enable early detection, coordinate evacuation, and ready hospital teams before ambulance arrival. The company has conducted clinical trials at hospitals in Israel and Europe and has examined hundreds of patients. Led by CEO Oren Dror and founded in 2018, CVAid plans to expand operations and accelerate its business reach using the new funds.